CY1123033T1 - Σπειροκυκλικοι αναστολεις της καθεψινης c - Google Patents

Σπειροκυκλικοι αναστολεις της καθεψινης c

Info

Publication number
CY1123033T1
CY1123033T1 CY20191101154T CY191101154T CY1123033T1 CY 1123033 T1 CY1123033 T1 CY 1123033T1 CY 20191101154 T CY20191101154 T CY 20191101154T CY 191101154 T CY191101154 T CY 191101154T CY 1123033 T1 CY1123033 T1 CY 1123033T1
Authority
CY
Cyprus
Prior art keywords
cathepsin
spirocyclic
inhibitors
dipeptidyl
peptidase
Prior art date
Application number
CY20191101154T
Other languages
English (en)
Inventor
Viktor VINTONYAK
Matthias Grauert
Marc Grundl
Alexander Pautsch
Original Assignee
Boehringer Ingelheim International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh
Publication of CY1123033T1 publication Critical patent/CY1123033T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Η εφεύρεση αυτή αφορά μια ένωση του τύπου (I), στον οποίο Α και Cy έχουν μία από τις σημασίες που αναφέρονται στην περιγραφή και στη χρήση της ως αναστολέα της Καθεψίνης C, φαρμακευτικές συνθέσεις που την περιέχουν και μεθόδους χρήσης αυτών ως παραγόντων για τη θεραπεία και/ή την πρόληψη νόσων που συνδέονται με δραστικότητα διπεπτιδυλο-πεπτιδάσης I, π.χ. αναπνευστικές νόσοι.
CY20191101154T 2014-09-12 2019-11-06 Σπειροκυκλικοι αναστολεις της καθεψινης c CY1123033T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14184613 2014-09-12
PCT/EP2015/070449 WO2016038007A1 (en) 2014-09-12 2015-09-08 Spirocyclic inhibitors of cathepsin c

Publications (1)

Publication Number Publication Date
CY1123033T1 true CY1123033T1 (el) 2021-10-29

Family

ID=51535355

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191101154T CY1123033T1 (el) 2014-09-12 2019-11-06 Σπειροκυκλικοι αναστολεις της καθεψινης c

Country Status (34)

Country Link
US (3) US9540373B2 (el)
EP (2) EP3191487B1 (el)
JP (2) JP2017526716A (el)
KR (1) KR102510588B1 (el)
CN (2) CN108047240B (el)
AP (1) AP2017009733A0 (el)
AU (1) AU2015314355B2 (el)
BR (1) BR112017003433B1 (el)
CA (1) CA2960916C (el)
CL (1) CL2017000432A1 (el)
CO (1) CO2017002268A2 (el)
CY (1) CY1123033T1 (el)
DK (1) DK3191487T3 (el)
EA (1) EA031376B1 (el)
ES (1) ES2749009T3 (el)
HK (1) HK1255362A1 (el)
HR (1) HRP20191756T1 (el)
HU (1) HUE047208T2 (el)
IL (1) IL250262B (el)
LT (1) LT3191487T (el)
MX (2) MX367316B (el)
MY (1) MY188382A (el)
NZ (1) NZ728684A (el)
PE (1) PE20170438A1 (el)
PH (1) PH12017500453A1 (el)
PL (1) PL3191487T3 (el)
PT (1) PT3191487T (el)
RS (1) RS59444B1 (el)
SA (1) SA517381064B1 (el)
SG (1) SG11201701633SA (el)
SI (1) SI3191487T1 (el)
TW (1) TWI687424B (el)
UA (1) UA118610C2 (el)
WO (1) WO2016038007A1 (el)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9018227B2 (en) 2010-03-19 2015-04-28 Indiana State University Nicotinic acetylcholine receptor agonists
NO2699580T3 (el) 2014-01-24 2018-02-24
WO2016016242A1 (en) * 2014-08-01 2016-02-04 Boehringer Ingelheim International Gmbh Substituted oxetanes and their use as inhibitors of cathepsin c
LT3191487T (lt) 2014-09-12 2019-10-10 Boehringer Ingelheim International Gmbh Katepsino c spirocikliniai inhibitoriai
WO2018162312A1 (en) * 2017-03-10 2018-09-13 Basf Se Spirocyclic derivatives
EP3749326A4 (en) * 2018-02-07 2021-11-03 Insmed Incorporated CERTAIN (2S) -N - [(1S) -1-CYANO-2-PHENYLETHYL] -1,4-OXAZEPAN-2-CARBOXAMIDE FOR THE TREATMENT OF VASCULITIDES ASSOCIATED WITH ANCA
KR20210032431A (ko) 2018-07-17 2021-03-24 인스메드 인코포레이티드 루푸스 신염을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카복스아미드
CN110256429B (zh) * 2019-06-17 2021-06-22 广东药科大学 一种具有螺环结构的氨基嘧啶类化合物及其制备方法和应用
CN110257504A (zh) * 2019-06-30 2019-09-20 中南大学 一种难治性哮喘检测标记物的筛选方法及其应用
KR20230117738A (ko) * 2020-12-04 2023-08-09 레이스톤 바이오파마 컴퍼니 리미티드 카텝신 c의 소분자 억제제 및 이의 의약적 용도
WO2023243601A1 (ja) * 2022-06-13 2023-12-21 モジュラス株式会社 アザシクロアルキルカルボニル環状アミン化合物
WO2024008680A1 (en) 2022-07-06 2024-01-11 Chiesi Farmaceutici S.P.A. Azetidine derivatives and use thereof as dipeptidyl peptidase 1 inhibitors
WO2024088307A1 (zh) * 2022-10-26 2024-05-02 上海壹迪生物技术有限公司 一种新型肽基腈类化合物及其应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4125727A (en) 1976-10-18 1978-11-14 American Cyanamid Company Method of preparing imidazoisoindolediones
GB8922355D0 (en) 1989-10-04 1989-11-22 British Telecomm Sealing gland
GEP20012487B (en) 1998-09-16 2001-07-25 Merab Lomia Use of Chemical Agent 5-carbarnoyl-5H-Dibenz (b,f) azepin, its Derivatives and Analogues by New Purpose
US8933236B2 (en) 2012-05-22 2015-01-13 Xenon Pharmaceuticals Inc. N-substituted benzamides and methods of use thereof
US6960597B2 (en) 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
JP4365094B2 (ja) 2001-03-02 2009-11-18 メルク フロスト カナダ リミテツド カテプシンシステインプロテアーゼ阻害薬
TW200306189A (en) 2002-03-21 2003-11-16 Merz Pharma Gmbh & Co Kgaa Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists
EP1638925A1 (en) 2003-06-18 2006-03-29 Prozymex A/S Protease inhibitors
TW200528440A (en) 2003-10-31 2005-09-01 Fujisawa Pharmaceutical Co 2-cyanopyrrolidinecarboxamide compound
US20060223846A1 (en) 2005-03-08 2006-10-05 Dyatkin Alexey B Aza-bridged-bicyclic amino acid derivatives as alpha4 integrin antagonists
CN101460462B (zh) * 2006-06-01 2013-07-31 塞诺菲-安万特股份有限公司 作为蛋白酶抑制剂的螺环腈类
AU2007301126A1 (en) 2006-09-28 2008-04-03 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
JP5240201B2 (ja) 2007-10-12 2013-07-17 富士通株式会社 Ｉｐ電話自動試験システム及び方法
AU2008334444B2 (en) 2007-12-12 2011-12-15 Astrazeneca Ab Peptidyl nitriles and use thereof as dipeptidyl peptidase I inhibitors
SG175090A1 (en) 2009-05-07 2011-11-28 Astrazeneca Ab Substituted 1-cyanoethylheterocyclylcarboxamide compounds 750
WO2010142985A1 (en) 2009-06-10 2010-12-16 Astrazeneca Ab Substituted n-[1-cyano-2-(phenyl)ethyl]piperidin-2-ylcarboxmide compounds 761
WO2012119941A1 (en) 2011-03-04 2012-09-13 Prozymex A/S Peptidyl nitrilcompounds as peptidase inhibitors
US8999975B2 (en) 2011-09-19 2015-04-07 Boehringer Ingelheim International Gmbh Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C
CN104379559B (zh) 2012-04-27 2016-11-09 葛兰素集团有限公司 化合物
US9056874B2 (en) 2012-05-04 2015-06-16 Novartis Ag Complement pathway modulators and uses thereof
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
JO3459B1 (ar) 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
KR102215272B1 (ko) 2012-09-28 2021-02-15 이그니타, 인코포레이티드 비정형 단백질 키나제 c의 아자퀴나졸린 억제제
US20140100236A1 (en) * 2012-10-09 2014-04-10 Boehringer Ingelheim International Gmbh Use of selectively moisture-adjusted tabletting material in the production of mechanically stable tablets which contain at least one hydrate-forming active substance and/or adjuvant relevant to the mechanical stability of the tablets, particularly arginine-containing tablets
US10092572B2 (en) 2012-10-15 2018-10-09 Epizyme, Inc. Substituted benzene compounds
HUE035335T2 (en) 2012-10-16 2018-05-02 Janssen Pharmaceutica Nv ROR-gamma-T methylene-linked quinolinyl modulators
US9181271B2 (en) 2012-11-01 2015-11-10 Incyte Holdings Corporation Tricyclic fused thiophene derivatives as JAK inhibitors
SG10201707095QA (en) 2012-12-21 2017-09-28 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
US9233974B2 (en) 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
WO2014100818A1 (en) 2012-12-21 2014-06-26 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
EA201591051A1 (ru) 2013-02-08 2016-06-30 Селджен Авиломикс Рисерч, Инк. Ингибиторы erk и варианты их применения
JP6441831B2 (ja) * 2013-03-14 2018-12-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング カテプシンｃの置換２−アザ−ビシクロ［２．２．２］オクタン−３−カルボン酸（ベンジル−シアノ−メチル）−アミド阻害剤
KR20150131224A (ko) 2013-03-14 2015-11-24 노파르티스 아게 돌연변이 idh의 억제제로서의 3-피리미딘-4-일-옥사졸리딘-2-온
AU2014230814B2 (en) * 2013-03-14 2017-12-21 Boehringer Ingelheim International Gmbh Substituted 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of Cathepsin C
AR095426A1 (es) 2013-03-14 2015-10-14 Onyx Therapeutics Inc Inhibidores tripeptídicos de la epoxicetona proteasa
JO3383B1 (ar) 2013-03-14 2019-03-13 Lilly Co Eli مثبطات cdc7
KR20150126623A (ko) 2013-03-14 2015-11-12 뉴링크 제네틱스 코퍼레이션 트립토판 대사로 인한 면역억제의 억제제로서의 삼환식 화합물
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
JO3773B1 (ar) 2013-03-14 2021-01-31 Janssen Pharmaceutica Nv معدلات p2x7
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
DK3137136T3 (en) * 2014-04-29 2018-07-23 Carebay Europe Ltd DEVICE FOR ADJUSTING DEADLINE DEPTH
JP2017521308A (ja) 2014-07-03 2017-08-03 ブリヂストン アメリカズ タイヤ オペレーションズ、 エルエルシー リムガード上のサイドウォールの装飾
BR112017004580A2 (pt) 2014-09-12 2018-01-23 GlaxoSmithKline Intellectual Property composto, composição farmacêutica, produto de combinação, uso de um composto ou sal farmaceuticamente aceitável, e, método de tratamento.
TW201625591A (zh) 2014-09-12 2016-07-16 美國禮來大藥廠 吖丁啶基氧苯基吡咯啶化合物
LT3191487T (lt) * 2014-09-12 2019-10-10 Boehringer Ingelheim International Gmbh Katepsino c spirocikliniai inhibitoriai
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa

Also Published As

Publication number Publication date
US20170073352A1 (en) 2017-03-16
CN107074870B (zh) 2019-07-12
SA517381064B1 (ar) 2021-02-07
US20160075704A1 (en) 2016-03-17
NZ728684A (en) 2022-09-30
US9540373B2 (en) 2017-01-10
USRE47636E1 (en) 2019-10-08
SG11201701633SA (en) 2017-03-30
CA2960916A1 (en) 2016-03-17
CA2960916C (en) 2023-03-07
PH12017500453B1 (en) 2017-07-31
BR112017003433A2 (pt) 2017-11-28
WO2016038007A1 (en) 2016-03-17
EA201790576A1 (ru) 2017-08-31
PL3191487T3 (pl) 2020-03-31
UA118610C2 (uk) 2019-02-11
MY188382A (en) 2021-12-07
ES2749009T3 (es) 2020-03-18
CL2017000432A1 (es) 2017-10-20
KR20170054489A (ko) 2017-05-17
JP2018044011A (ja) 2018-03-22
RS59444B1 (sr) 2019-11-29
PE20170438A1 (es) 2017-04-28
AU2015314355A1 (en) 2017-02-16
IL250262B (en) 2020-03-31
US9879026B2 (en) 2018-01-30
PT3191487T (pt) 2019-11-18
MX2019009695A (es) 2019-10-07
EP3511331A1 (en) 2019-07-17
PH12017500453A1 (en) 2017-07-31
HUE047208T2 (hu) 2020-04-28
CN108047240B (zh) 2020-08-04
SI3191487T1 (sl) 2019-12-31
MX367316B (es) 2019-08-15
HK1255362A1 (zh) 2019-08-16
AU2015314355B2 (en) 2019-06-20
JP6360961B2 (ja) 2018-07-18
EP3191487A1 (en) 2017-07-19
CO2017002268A2 (es) 2017-06-20
KR102510588B1 (ko) 2023-03-17
CN108047240A (zh) 2018-05-18
BR112017003433B1 (pt) 2023-11-14
MX2017003156A (es) 2017-05-23
TW201625647A (zh) 2016-07-16
IL250262A0 (en) 2017-03-30
JP2017526716A (ja) 2017-09-14
LT3191487T (lt) 2019-10-10
TWI687424B (zh) 2020-03-11
AP2017009733A0 (en) 2017-02-28
HRP20191756T1 (hr) 2019-12-27
EA031376B1 (ru) 2018-12-28
DK3191487T3 (da) 2019-10-28
EP3191487B1 (en) 2019-08-07
CN107074870A (zh) 2017-08-18

Similar Documents

Publication Publication Date Title
CY1123033T1 (el) Σπειροκυκλικοι αναστολεις της καθεψινης c
CY1125214T1 (el) Ενωσεις ν-((ετ)αρυλμεθυλ)-ετεροαρυλ-καρβοξαμιδιων ως αναστολεις καλλικρεϊνης πλασματος
CY1122186T1 (el) Μεθοδοι θεραπειας καρκινου
CY1123595T1 (el) Παραγωγα χολικου οξεος ως αγωνιστες fxr/tgr5
CY1124215T1 (el) Μκ2 αναστολεις και χρησεις αυτων
MX2018000396A (es) Compuestos aza sustituidos como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak-4).
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
EA201790271A1 (ru) Ингибиторы гликозидазы
EA201691857A1 (ru) Соединения, применимые в качестве иммуномодуляторов
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201691354A1 (ru) Терапевтические ингибирующие соединения
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
CR20160456A (es) Compuestos de heteroarilo o arilo bibíclicos fusionados
CU24389B1 (es) Compuestos de heterociclilo bicíclico como inhibidores de irak4
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
CY1120751T1 (el) Αναστολεις ετεροδικυκλοαρυλιου του rorc2 και μεθοδοι χρησης αυτων
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
EA201790266A1 (ru) Индолы для применения при инфекции, вызванной вирусом гриппа
BR112016018062A8 (pt) compostos terapêuticos, composição farmacêutica e usos
BR112017013440A2 (pt) compostos de isoquinolina para o tratamento de hiv
CY1122313T1 (el) Ορβεπιταντη για την αγωγη του χρονιου κνησμου
EA201691481A1 (ru) ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ
EA201591406A1 (ru) C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич
EA201791174A1 (ru) Антимикотическое соединение